| [1] |
Cufer T, Knez L. Update on systemic therapy of advanced nonsmall- cell lung cancer[J]. Expert Rev Anticancer Ther, 2014, 14 (10): 1189-203.
|
| [2] |
Han B, Zhou X, Zhang RX, et al. Mutations of the epidermal growth factor receptor gene in NSCLC patients[J]. Oncol Lett, 20 11, 2(6): 1233-7.
|
| [3] |
Chang CC, Chi KH, Kao SJ, et al. Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience[J]. Lung Cancer, 20 11, 73(2): 189-94.
|
| [4] |
Zhang XN, Zou W, Ma JA, et al. Change of radiosensitivity and reversal of drug resistance in gefitinib-resistant lung adenocarcinoma cell caused by T790M Mutation[J]. Zhongguo Quan Ke Yi Xue, 2014, 10(30): 3570-4. [张星南, 邹文, 马进安, 等. T790M突变所致吉非替尼耐药肺腺癌细胞放射敏感性变化 及耐药性逆转的研究[J]. 中国全科医学, 2014, 10(30): 3570-4.]
|
| [5] |
Engelman JA, Jänne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall cell lung cancer[J]. Clin Cancer Res, 2008, 14(10): 2895-9.
|
| [6] |
Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib[J]. Proc Nati Acad Sci USA, 2007, 104(52): 20932-7.
|
| [7] |
Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP [J]. Proc Nati Acad Sci USA, 2008, 105(6): 2070-5.
|
| [8] |
Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib[J]. Proc Nati Acad Sci USA, 2005, 102(21): 7665-70.
|
| [9] |
Godin-Heymann N, Ulkus L, Brannigan BW, et al. The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor[J]. Mol Cancer Ther, 2008, 7(4): 874-9.
|
| [10] |
Kokubo Y, Gemma A, Noro R, et al. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)[J]. Br J Cancer, 2005, 92(9): 1711-9.
|
| [11] |
Lee AJ , Endesfelder D, Rowan A , et al. Chromosomal instability confers intrinsic multidrug resistance[J]. Cancer Res, 2011, 71(5): 18 58-70.
|
| [12] |
Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine [J]. Br J Cancer, 2010, 103(8): 1139-43.
|
| [13] |
Navin N, Kendall J, Troge J, et al. Tumour evolution inferred by single-cell sequencing[J]. Nature, 2011, 472(7341): 90-4.
|
| [14] |
Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basallike breast cancer metastasis and xenograft[J]. Nature, 2010, 46 4(7291): 999-1005.
|
| [15] |
Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer[J]. Nature, 2010, 46 7(7319): 1114-7.
|
| [16] |
Norihisa Y, Nagata Y, Takayama K, et al. Stereotactic body radiotherapy for oligometastatic lung tumors[J]. Int J Radiat Oncol Biol Phys, 2008, 72(2): 398-403.
|
| [17] |
Yu HA, Sima CS, Huang J, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors[J]. J Thorac Oncol, 2013, 8(3): 346-51.
|
| [18] |
Voltolini L, Rapicetta C, Luzzi L, et al. Surgical treatment of synchronous multiple lung cancer located in a different lobe or lung: high survival in node-negative subgroup[J]. Eur J Cardiothoracic Surg, 2010, 37(5): 1198-204.
|
| [19] |
Yano T, Haro A, Yoshida T, et al. Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer[J]. J Surg Oncol, 2010, 102(7): 852-5.
|
| [20] |
Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene addicted non-small cell lung cancer [J] J Thorac Oncol, 2012, 7(12): 1807-14.
|
| [21] |
Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing[J]. N Engl J Med, 2012, 366(10): 883-92.
|
| [22] |
Meyn RE, Munshi A, Haymach JV, et al. Receptor signaling as a regulatory mechanism of DNA repair[J]. Radiother Oncol, 2009, 92 (3): 316-22.
|
| [23] |
Myllynen L, Rieckmann T, Dahm-Daphi J, et al. In tumor cells regulation of DNA double strand break repair through EGF receptor involves both NHEJ and HR and is independent of p53 and K-Ras status[J]. Radiother Oncol, 2011, 101(1): 147-51.
|
下载:
